ProfileGDS5678 / 1455584_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 48% 50% 49% 50% 50% 25% 47% 49% 49% 54% 49% 56% 48% 49% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.1803648
GSM967853U87-EV human glioblastoma xenograft - Control 23.2033550
GSM967854U87-EV human glioblastoma xenograft - Control 33.1761949
GSM967855U87-EV human glioblastoma xenograft - Control 43.1545150
GSM967856U87-EV human glioblastoma xenograft - Control 53.1528950
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6409225
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1735147
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1616749
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1455749
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.2996454
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1604549
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3879556
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1408148
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.1671949